SCHEMBL19862439

SCHEMBL19862439

CC(=O)NCc1ccc(NC(=O)N2c3nc(-c4cccc(C(F)(F)F)c4)ccc3N3CC[C@H]2C3)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.41
▸ TSHR P16473 1/20 0.41
▸ CCR2 P41597 1/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ KDM4C Q9H3R0 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ OPRM1 P35372 1/20 0.39
▸ OPRD1 P41143 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ CA9 Q16790 1/20 0.39
▸ NPY2R P49146 1/20 0.38
▸ KDM1A O60341 1/20 0.38
▸ MAOA P21397 1/20 0.38
▸ MAOB P27338 1/20 0.38
▸ TRPV4 Q9HBA0 1/20 0.38
▸ MEN1 O00255 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ TRPV1 Q8NER1 2/20 0.37
▸ IDH2 P48735 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16249987 0.96 KDM4E (0.41) KMT2ATSHRCCR2KDM4EALDH1A1
Trifluoroacetic Acid SCHEMBL16238731 0.93 KDM4E (0.40) KMT2ATSHRCCR2KDM4EALDH1A1
SCHEMBL17618888 0.91 NAMPT (0.42) KMT2ATSHRCA2CA9NPY2R
SCHEMBL16250003 0.90 CA2 (0.42) KMT2AKDM4EALDH1A1KDM4CTDP1
SCHEMBL19670419 0.90 KMT2A (0.38) KMT2ATSHRCCR2ALDH1A1CA2
SCHEMBL20632966 0.90 CA2 (0.39) KMT2ATSHRCCR2ALDH1A1CA2
Hydrochloric Acid SCHEMBL16238420 0.89 CA2 (0.42) KMT2AKDM4EALDH1A1KDM4CTDP1
SCHEMBL16754369 0.89 IDH2 (0.41) KMT2ATSHRKDM4EOPRM1OPRD1
SCHEMBL17618817 0.88 CA2 (0.41) KMT2AALDH1A1CA2CA9NPY2R
SCHEMBL16250002 0.88 KMT2A (0.37) KMT2ATSHRCCR2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180044338-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2018-02-15 — — US disclosed
US-20180044338-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2018-02-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180044338-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 KMT2A 1287/4885TSHR 2703/4885CCR2 4404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback